The Journal for ImmunoTherapy of Cancer (JITC) welcomes submissions in the following areas and related topics:
Tumor antigens, innate and adaptive anti-tumor immune mechanisms, immune regulation, immune response, cancer and inflammation, preclinical models, chemotherapy and radiotherapy interactions/combinations of chemotherapy and radiotherapy, other combination treatments with the antitumor immune response, and oncolytic viruses.
Reports on unusual or unexpected clinical cases that expand the field of general medical knowledge. Includes information on an unexpected association between diseases or symptoms, an unexpected event in the course of observing or treating a patient, findings that shed new light on the possible pathogenesis of the disease or an adverse effect, unique or rare features of the disease, and/or a unique therapeutic approach.
First-in-man clinical trials, phase II/III clinical studies, immune monitoring investigations, tumor microenvironment, host genetics and clinical outcome, combination therapies, and cell therapies.
Announcements and updates of cancer immunotherapy clinical trials in progress. Includes perspectives and implications of late stage pivotal clinical trials results and new regulatory approvals. Articles may also focus on other pertinent regulatory issues to help define a road map for navigating the clinical trial landscape.
Reaction to and/or perspectives on significant events in the field in the basic science area. May address a critical challenge, elaborate or extend a conversation of a focal article, provide an application of a theoretical perspective, or shed light on a particular issue in the field.
Predictive/prognostic biomarker studies, gene expression studies in cancer immunotherapy, serological immune biomarkers, multiparameter flow cytometry-defined immune biomarkers, high content immunohistological studies, clinical trial analyses and identification of novel immune biomarkers.
Fact/data-driven works that cumulate several articles of importance on a particular subject or research area in a review format with the goal of providing the state-of-the-art in the field. Includes recent major advances and discoveries, significant gaps in the research, current debates, and/or ideas of where research might go next.
Content freely available upon publication.
Articles published within 2-4 weeks of acceptance.
JITC touts an impact factor of 8.374, which it first received in June 2018. JITC’s impact factor ranks in the top 8 percent of all journals published in the categories of oncology and immunology.
Featured in six major indexing resources including:
Published by BioMed Central, a member of the Committee on Publishing Ethics.
Monthly JITC Digest sent to global experts and Twitter coverage.
Recipients Receive $1,000* and recognition at SITC's Annual Meeting.
*Papers published between August 2016 to September 2017 authored by SITC members are eligible for nomination for awards. Papers on which the first or senior author is a SITC member are eligible for consideration. Join SITC, renew your membership, or check your current membership status.
Submit your Manuscript to JITC
Join SITC members, Drs. Vincenzo Bronte, Lorenzo Galluzzi and Jérôme Galon, for the Primer on Cancer Immunology and Immunotherapy at the International Conference on Immunotherapy Radiotherapy Combinations Sept. 20–22 in Paris. Attention SITC members! ...
This two day program is divided into a lectures series presented by world class scientists in the field of immuno-oncology, and a hands-on workshop laboratory to explore the optimization and troubleshooting of Opal staining, multispectral image acquisition ...
Currently scfvs, antibody-derived single chain variable fragment based CAR to target CD19 antigen is the most common CAR strategy clinically used. But based on the cited article, tumor cells can be targeted also through use of non-antibody based approahes.This ...
Dear Dr. Ramakrishna, Below please find a short summary of immunotherapies targeting CD123, CD33. All can be found on clinicaltrials.gov. I have heard that the City of Hope (COH) CAR T cells anti-CD123 study is showing early promise, but I have no ...
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: firstname.lastname@example.org